Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29196037 | 0.80 | RAPGEF4 (0.33) | CYP1A2 | |
| SCHEMBL27343376 | 0.77 | ALDH1A1 (0.40) | — | |
| SCHEMBL1130807 | 0.77 | CA1 (0.40) | CYP1A2CYP2C19 | |
| SCHEMBL10763176 | 0.76 | — | — | |
| SCHEMBL4095040 | 0.76 | RAPGEF4 (0.42) | CYP1A2CYP2C19 | |
| SCHEMBL20160730 | 0.76 | ESR1 (0.35) | CYP1A2CYP2C19 | |
| SCHEMBL26314573 | 0.74 | RAPGEF4 (0.36) | — | |
| SCHEMBL24079377 | 0.74 | — | — | |
| SCHEMBL18461006 | 0.72 | IDO1 (0.33) | CYP1A2CYP2C19 | |
| SCHEMBL25949747 | 0.72 | EZH2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242471-A1 | THYROMIMETICS | AUTOBAHN THERAPEUTICS, INC. | 2023-08-03 | — | — | US | disclosed |
| WO-2022232320-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT | MERCK SHARP & DOHME CORP. (US) | 2022-11-03 | — | — | WO | disclosed |
| CN-103732632-B | Method for producing olefin block polymer using Group 4 transition metal complex | 住友化学株式会社 | 2017-07-07 | — | — | CN | disclosed |
| CN-103958548-B | Use the manufacture method of the olefin block polymers of multiple transition-metal catalyst | SUMITOMO CHEMICAL CO.,LTD. (JP) | 2016-05-18 | — | — | CN | disclosed |
| CN-103958548-A | Method for producing olefin block polymer using plurality of types of transition metal catalysts | SUMITOMO CHEMICAL CO | 2014-07-30 | — | — | CN | disclosed |
| CN-101878236-B | Ethylene-alpha-olefin copolymer and molded body | SUMITOMO CHEMICAL CO | 2014-05-07 | — | — | CN | disclosed |
| CN-103732632-A | Method for producing olefin block polymer using group 4 transition metal complex | SUMITOMO CHEMICAL CO | 2014-04-16 | — | — | CN | disclosed |
| WO-2009104785-A1 | CATALYST COMPONENT FOR POLYMERIZATION OF ETHYLENE AND PROCESS FOR PRODUCING ETHYLENE POLYMER (1) | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242471-A1 | THYROMIMETICS | TPO, THOP1, THRB | CYP1A2 2241/4885CYP2C19 3817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.